Rituximab + Immunotherapy in Follicular Lymphoma

Phase 1 Terminated 24 enrolled Dana-Farber Cancer Institute Pfizer · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This research study is studying several new investigational drug combinations as a possible treatment for follicular lymphoma. The drugs involved are: * Rituximab * Utomilumab * Avelumab * PF-04518600

Timeline

Start: 2018-10-30
Primary completion: 2021-07-23
Completion: 2023-07-30

Outcome

Outcome not reported

Stopped (Enrollment): “Stopped was stopped prematurely due to drug manufacturer withdrawing supply/funding. Patients already enrolled on study were allowed to continue treatment.”

Publications

Merryman RW, Redd RA, Freedman AS, Ahn IE, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen ED, Kim AI, LaCasce AS, Ng S, Odejide OO, Parry EM, Isufi I, Kline J, Cohen JB, Mehta-Shah N, Bartlett NL, Mei M, Kuntz TM, Wolff J, Rodig SJ, Armand P, Jacobson CA. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma. Ann Hematol. 2024 Jan;103(1):185-198. doi: 10.1007/s00277-023-05475-0. Epub 2023 Oct 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Avelumab	Monoclonal antibody	3 mg/kg	Intravenous
Subject	Avelumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Ivuxolimab	Monoclonal antibody	0.3 mg/kg	Intravenous
Subject	Rituximab	Monoclonal antibody	—	Intravenous
Subject	Utomilumab	Monoclonal antibody	—	Intravenous